{
    "clinical_study": {
        "@rank": "18185", 
        "arm_group": [
            {
                "arm_group_label": "Active high", 
                "arm_group_type": "Active Comparator", 
                "description": "Probiotic, high dose"
            }, 
            {
                "arm_group_label": "Active low", 
                "arm_group_type": "Active Comparator", 
                "description": "Probiotic, low dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to analyse the effect of a probiotic supplement on functional\n      intestinal symptoms among subjects diagnosed with irritable bowel syndrome (IBS)."
        }, 
        "brief_title": "Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Irritable Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Irritable Bowel Syndrome", 
                "Gastrointestinal Diseases", 
                "Signs and Symptoms, Digestive"
            ]
        }, 
        "detailed_description": {
            "textblock": "The aim of the intervention is to analyse the effect of a probiotic supplement in a\n      dose-responsive set up on functional intestinal symptoms among subjects diagnosed with IBS\n      according to Rome III criteria. Subjective assessment of bowel symptoms, quality of life,\n      anxiety and depression and adequate relief will be assessed as with questionnaires as\n      outcome measures. The intestinal microbiota will be analysed from faecal samples."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects aged 18 to 65 fulfilling Rome III criteria for IBS will be recruited.\n             Sufficient general health and orientation for participating in the study is required\n             and will be evaluated by the MDs.\n\n        Exclusion Criteria:\n\n          -  Diagnosed or suspected organic gastrointestinal diseases or severely impaired general\n             health."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "390", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728610", 
            "org_study_id": "IBS-2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active high", 
                "description": "Higher dose of probiotic supplement", 
                "intervention_name": "Probiotic  (Active high)", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Lactobacillus"
            }, 
            {
                "arm_group_label": "Active low", 
                "description": "Lower dose of probiotic supplement", 
                "intervention_name": "Probiotic (Active low)", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Lactobacillus"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Maltodextrin as placebo"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "irritable bowel syndrome", 
            "probiotic", 
            "pain", 
            "bloating", 
            "diarrhoea", 
            "constipation"
        ], 
        "lastchanged_date": "October 21, 2013", 
        "location": [
            {
                "contact": {
                    "email": "liisa.knaapi@dupont.com", 
                    "last_name": "Liisa Knaapi", 
                    "phone": "+358 40 577 2965"
                }, 
                "contact_backup": {
                    "email": "paivi.kuusniemi@mehilainen.fi", 
                    "last_name": "P\u00e4ivi Kuusniemi"
                }, 
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland", 
                        "zip": "00260"
                    }, 
                    "name": "Mehil\u00e4inen T\u00f6\u00f6l\u00f6"
                }, 
                "investigator": {
                    "last_name": "Lea Veijola, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Laura Varantola, Research Nurse", 
                    "phone": "02-4140207"
                }, 
                "contact_backup": {
                    "last_name": "Anu Lillbacka, Research Nurse", 
                    "phone": "02-4140207"
                }, 
                "facility": {
                    "address": {
                        "city": "Turku", 
                        "country": "Finland", 
                        "zip": "20100"
                    }, 
                    "name": "Mehil\u00e4inen Turku"
                }, 
                "investigator": [
                    {
                        "last_name": "Helena Kemppainen, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Tiina Kojo, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms (IBS-2)", 
        "overall_contact": {
            "email": "anna.lyra@dupont.com", 
            "last_name": "Anna Lyra, PhD"
        }, 
        "overall_contact_backup": {
            "email": "anneli.tarpila@dupont.com", 
            "last_name": "Anneli Tarpila, PhD"
        }, 
        "overall_official": [
            {
                "affiliation": "Herttoniemi Hospital", 
                "last_name": "Lea Veijola, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "DuPont Nutrition and Health", 
                "last_name": "Arthur Ouwehand, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "DuPont Nutrition and Health", 
                "last_name": "Sampo Lahtinen, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "DuPont Nutrition and Health", 
                "last_name": "Anneli Tarpila, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "DuPont Nutrition and Health", 
                "last_name": "Anna Lyra, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Validated questionnaire", 
            "measure": "Change in functional bowel symptoms", 
            "safety_issue": "No", 
            "time_frame": "0 weeks, 4 weeks, 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728610"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Validated questionnaire", 
                "measure": "Change in quality of life", 
                "safety_issue": "No", 
                "time_frame": "0 weeks, 4 weeks, 12 weeks"
            }, 
            {
                "description": "Validated questionnaire", 
                "measure": "Change in anxiety and depression", 
                "safety_issue": "No", 
                "time_frame": "0 weeks, 4 weeks and 12 weeks"
            }, 
            {
                "description": "Weekly question", 
                "measure": "Adequate relief", 
                "safety_issue": "No", 
                "time_frame": "Weekly over 3 month intervention"
            }, 
            {
                "description": "Detection and quantification of microbes from faecal samples", 
                "measure": "Change in faecal microbiota", 
                "safety_issue": "No", 
                "time_frame": "0 weeks, 4 weeks, 12 weeks"
            }, 
            {
                "description": "Recording of adverse events and serious adverse events", 
                "measure": "Safety of investigational product", 
                "safety_issue": "Yes", 
                "time_frame": "Throughout the intervention phase"
            }
        ], 
        "source": "Danisco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Danisco", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}